Additional file 1: Supplementary Table 1. Inhibitor concentrations. Supplementary Table 2. Antibodies and reagents for flow cytometry. Supplementary Table 3. Primer for quantitative real‐time PCR. Supplementary Table 4. Antibodies for western blot. Supplementary Figure 1. Gating strategy for FACS analyses. Supplementary Figure 2. TKIs affect CML cell metabolism. Supplementary Figure 3. Unpooled data of Figure 1b,c. Supplementary Figure 4. Imatinib has no significant effect on oxPhos complex expression. Supplementary Figure 5. Thapsigargin increases the lethality of CML cells in combination with TKIs. Supplementary Figure 6. Oligomycin induces ER stress and imatinib blocks ATF4 upregulation (uncropped images of Figure 3a). Supplementary Figu...
Figure S1. Gating strategy for 2 h flow-based cytotoxicity assay. Target cells were stained with PKH...
Dose response curve and chemoprotection of leukemia cells by MSC. a-c Dose response curve showing pe...
Additional file 1: Table S1. Clinical characteristics of AML patient-derived primary cells. Table S2...
Additional file 1: Table S1. The clinical characteristics of chronic myeloid leukemia patients recru...
Figure S1. Dose-response curves performed to verify K562 IM resistance: significant differences in L...
Table S1. Patient’s characteristic of gene expression cohort. Table S2. Patient’s characteristic ex ...
(A/B) Ba/F3 vector cells and cells transformed with pBABE Bcr-Abl were exposed to the indicated inhi...
Figure S3. Supporting data for Fig. 3. (A), (B) Quantification of protein from the experiments, norm...
Figure S2. Supporting data for Fig. 2. (A) K562 cells were treated with ZFN-L and ZFN-R for 48 h and...
Figure S5. Supporting data for Fig. 4. (A) The colony formation ability of K562 and K562/G01 cells w...
Figure S1. Expression of ZFNs proteins in K562 cells. (A) The proteins of K562 cells were collected ...
Figure S1. Flow cytometry analysis of CD45+CD33+ leukemia cells in peripheral blood of 14 and 7Â day...
Additional file includes supplementary materials and methods, supplementary tables S1-S2 and suppl...
Figure S2. K562-R response to Thiostrepton, Danusertib and Volasertib, relative to Ă-catenin intera...
Figure S4. Supporting data for Fig. 4. (A) The percentage of apoptotic cells was determined by 7-AAD...
Figure S1. Gating strategy for 2 h flow-based cytotoxicity assay. Target cells were stained with PKH...
Dose response curve and chemoprotection of leukemia cells by MSC. a-c Dose response curve showing pe...
Additional file 1: Table S1. Clinical characteristics of AML patient-derived primary cells. Table S2...
Additional file 1: Table S1. The clinical characteristics of chronic myeloid leukemia patients recru...
Figure S1. Dose-response curves performed to verify K562 IM resistance: significant differences in L...
Table S1. Patient’s characteristic of gene expression cohort. Table S2. Patient’s characteristic ex ...
(A/B) Ba/F3 vector cells and cells transformed with pBABE Bcr-Abl were exposed to the indicated inhi...
Figure S3. Supporting data for Fig. 3. (A), (B) Quantification of protein from the experiments, norm...
Figure S2. Supporting data for Fig. 2. (A) K562 cells were treated with ZFN-L and ZFN-R for 48 h and...
Figure S5. Supporting data for Fig. 4. (A) The colony formation ability of K562 and K562/G01 cells w...
Figure S1. Expression of ZFNs proteins in K562 cells. (A) The proteins of K562 cells were collected ...
Figure S1. Flow cytometry analysis of CD45+CD33+ leukemia cells in peripheral blood of 14 and 7Â day...
Additional file includes supplementary materials and methods, supplementary tables S1-S2 and suppl...
Figure S2. K562-R response to Thiostrepton, Danusertib and Volasertib, relative to Ă-catenin intera...
Figure S4. Supporting data for Fig. 4. (A) The percentage of apoptotic cells was determined by 7-AAD...
Figure S1. Gating strategy for 2 h flow-based cytotoxicity assay. Target cells were stained with PKH...
Dose response curve and chemoprotection of leukemia cells by MSC. a-c Dose response curve showing pe...
Additional file 1: Table S1. Clinical characteristics of AML patient-derived primary cells. Table S2...